Clal Biotechnology Valuation Multiples

Clal Biotechnology is valued at $11M as of October 2026. In the last fiscal year, Clal Biotechnology EBITDA was ($7M).

Clal Biotechnology Overview

About Clal Biotechnology

Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.


Founded

1998

HQ

Israel

Employees

N/A

Website

cbi.co.il

Sectors

Financials (Last FY)

Revenue: -
EBITDA: ($7M)

EV

$17M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Clal Biotechnology Financials

Clal Biotechnology reported last fiscal year revenue of - and negative EBITDA of ($7M).

In the same fiscal year, Clal Biotechnology generated ($7M) in EBITDA losses and had net loss of ($4M).


Clal Biotechnology P&L

In the most recent fiscal year, Clal Biotechnology reported revenue of - and EBITDA of ($7M).

Clal Biotechnology is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Clal Biotechnology
Last FY2025202620272028
EBITDA($7M)($7M)
Net Profit($4M)($4M)
Net Debt$5M-

Financial data powered by Morningstar, Inc.

Clal Biotechnology Stock Performance

Clal Biotechnology has current market cap of $11M, and enterprise value of $17M.

Market Cap Evolution


Clal Biotechnology's stock price is $0.07.

Clal Biotechnology has an EPS (earnings per share) of $-0.03.

See more trading valuation data for Clal Biotechnology
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$17M$11M-9.2%---$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Clal Biotechnology Valuation Multiples

Clal Biotechnology trades at (2.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Clal Biotechnology

Clal Biotechnology Financial Valuation Multiples

As of October 20, 2026, Clal Biotechnology has market cap of $11M and EV of $17M.

Clal Biotechnology has a P/E ratio of (2.6x).

Last FY2025202620272028
EV/EBITDA(2.5x)(2.5x)
EV/EBIT(11.0x)(11.0x)
P/E(2.6x)(2.6x)
EV/FCF(11.2x)(11.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Clal Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Clal Biotechnology Competitors

Clal Biotechnology competitors include Hub Girişim, Bio Meat Foodtech, CodeLab Capital, Unfold.vc, Azevedo & Travassos Energia, Netcapital, Tern, ICU Girisim Sermayesi, Next Dynamics and HYLQ Strategy.

Most Clal Biotechnology public comparables operate across PE & VC.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Hub Girişim$44K($11M)258.5x-(1.0x)-
Bio Meat Foodtech------
CodeLab Capital$1M($1M)7.7x-(6.8x)-
Unfold.vc($1M)($1M)(8.3x)-(6.6x)-
Azevedo & Travassos Energia$567K($830K)18.9x-(12.9x)-
Netcapital$869K($28M)16.6x-(0.5x)-
Tern$72K($7M)179.2x-(1.9x)-
ICU Girisim Sermayesi-($4M)--(2.1x)-

This data is available for Pro users. Sign up to see all Clal Biotechnology competitors and their valuation data.

Start Free Trial

Investments by Clal Biotechnology

Clal Biotechnology has invested in 11 companies to date.

Latest investment by Clal Biotechnology was on August 3rd 2023. Clal Biotechnology invested in TytoCare in their $49M Series E round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Clal Biotechnology

TytoCare
Sight Diagnostics
Cadent Therapeutics
Elicio Therapeutics
Description
TytoCare is a Tel Aviv-headquartered digital health company offering remote examination devices and telehealth platforms. TytoHome enables consumer self-exams of heart, lungs, skin, throat, ears, and temperature, while TytoPro supports clinicians and TytoClinic serves clinics. The system includes AI-guided tools, video consultations, and cloud analytics, used by over 1,000 healthcare organizations globally.
Sight Diagnostics is a Jerusalem-headquartered medtech company developing AI-powered blood analyzers. Its OLO device, FDA 510(k)-cleared in 2020, performs complete blood counts from finger-prick samples in minutes using digital microscopy. Previously, Parasight conducted nearly one million malaria tests in 24 countries. Sight maintains commercial operations across five continents with offices in London and New York.
Cambridge, Massachusetts-based Cadent Therapeutics develops precision neuroscience drugs that modulate brain rhythms for neurological disorders. Founded in 2010, the company targets movement and cognitive impairments with first-in-class molecules combining target-specific design, patient stratification, and quantitative endpoints. Its pipeline addresses Parkinson's disease and other brain rhythm dysfunctions.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
HQ CountryUnited StatesIsraelUnited StatesUnited States
HQ City
New York City, NY
Tel Aviv
-
-
Deal Date3 Aug 20235 Aug 202029 Apr 20202 Oct 2019
RoundSeries ESeries DSeries BSeries B
Raised$49M$71M$15M$33M
InvestorsMemorialCare Innovation Fund; Healthcare of Ontario Pension Plan (HOOPP); Clal Biotechnology; Insight PartnersNew Alliance Capital; Koch Disruptive Technologies; OurCrowd; Clal Biotechnology; Longliv Ventures; GO CAPITALCowen Healthcare Investments; Novartis; Access Industries; Qiming Venture Partners; Atlas Venture; Clal BiotechnologyEFung Capital; Clal Biotechnology; Livzon Pharmaceutical Group
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Clal Biotechnology investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Clal Biotechnology

When was Clal Biotechnology founded?Clal Biotechnology was founded in 1998.
Where is Clal Biotechnology headquartered?Clal Biotechnology is headquartered in Israel.
Is Clal Biotechnology publicly listed?Yes, Clal Biotechnology is a public company listed on Tel Aviv Stock Exchange.
What is the stock symbol of Clal Biotechnology?Clal Biotechnology trades under CBI ticker.
When did Clal Biotechnology go public?Clal Biotechnology went public in 2007.
Who are competitors of Clal Biotechnology?Clal Biotechnology main competitors include Hub Girişim, Bio Meat Foodtech, CodeLab Capital, Unfold.vc, Azevedo & Travassos Energia, Netcapital, Tern, ICU Girisim Sermayesi, Next Dynamics, HYLQ Strategy.
What is the current market cap of Clal Biotechnology?Clal Biotechnology's current market cap is $11M.
Is Clal Biotechnology profitable?No, Clal Biotechnology is not profitable.
How many companies Clal Biotechnology has acquired to date?Clal Biotechnology hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Clal Biotechnology has invested to date?As of October 2026, Clal Biotechnology has invested in 11 companies.
What was the last Clal Biotechnology investment?On 3rd August 2023 Clal Biotechnology invested in TytoCare, participating in a $49M Series E round, alongside MemorialCare Innovation Fund, Healthcare of Ontario Pension Plan (HOOPP), and Insight Partners.

See public comps similar to Clal Biotechnology

Lists including Clal Biotechnology

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial